Skip to main content

Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

OCS Liver PROTECT Continued Access Protocol

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about OCS Liver PROTECT Continued Access Protocol

STRIVE Post-Market Registry Study

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about STRIVE Post-Market Registry Study

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer (LIGHTHOUSE)

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Evaluation of the Asthma Management Program to Promote Activity for Students in Schools (Asthma-PASS)

Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Submitted by Anonymous (not verified) on Tue, 07/19/2022 - 18:36
  • Read more about Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 78
  • Page 79
  • Page 80
  • Page 81
  • Page 82
  • Page 83
  • Page 84
  • Page 85
  • Page 86
  • …
  • Next page Next
  • Last page Last
Subscribe to